Assessment of the antiviral activity of 2HCl*H-His-Rim compound compared to the anti-influenza drug Arbidol for influenza caused by A/duck/Novosibirsk/56/05 (H5N1) (Influenza A virus, Alphainfluenzavirus, Orthomyxoviridae)
Open Access
- 20 December 2019
- journal article
- research article
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 64 (6) , 268-273-273
Abstract
Introduction. The emergence of influenza virus strains with drug resistance to antiviral drugs requires finding new compounds, potential direct-acting inhibitors. Аdamantane compounds drugs used since the 1960s have lost their activity the resulting due to resistance. Only neuraminidase inhibitors such as zanamivir and oseltamivir have been approved by WHO for influenza treatment. The Russian pharmaceutical drug Arbidol (Umifenovirum) is actively used in Russia. This drug is used to treat influenza in Russia, China and most post-Soviet republics. This work presents a new derivative of aminoadamantane - dichlorohydrate L-histidyl-1-adamantayl ethylamine (2HCl*H-His-Rim), which showed a high level of inhibition of strains of influenza virus A in vitro.Objectives. Comparison of antiviral properties of the new synthetic low-molecular inhibitor of influenza A virus replication and Arbidol drug pharmacy.Methods. The compound 2HCl*H-His-Rim was obtained by classical peptide synthesis methods. It was identified by methods of mass spectrometry, infrared spectroscopy (IR) and nuclear magnetic resonance spectroscopy (NMR). Its antiviral properties have been studied in vitro for monolayer of cells Vero-E6 infected with a high-virulent strain of A/duck/Novosibirsk/56/06 (H5N1) influenza virus at various injection schemes of the investigated compounds.The results. The antiviral activity of the 2HCl*H-His-Rim compound against the highly pathogenic strain of the influenza A/H5N1 virus was slightly higher than for the known pharmacy drug arbidol.Discussion. The difference in antiviral activity of these two compounds is explained by different mechanisms of action on the viral particle.Conclusion. The 2HCl*H-His-Rim compound can be recommended as a candidate for preclinical and clinical trials in order to obtain an etiotropic antiviral drug based on it, due to its high efficacy and economic and synthetic availability. The synthetic compound 2HCl*H-His-Rim acts on influenza A virus variants resistant to Rimantadine and Amantadine.Keywords
This publication has 11 references indexed in Scilit:
- Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne FlavivirusesViruses, 2018
- Amino Acid Derivatives of Adamantane Carbocycle are Capable of Inhibiting Replication of Highly Virulent Avian Influenza A/H5N1 VirusBulletin of Experimental Biology and Medicine, 2014
- Inhibition of influenza hemagglutinin with the antiviral inhibitor arbidol using a proteomics based approach and mass spectrometryAntiviral Research, 2013
- Design of inhibitors of influenza virus membrane fusion: Synthesis, structure–activity relationship and in vitro antiviral activity of a novel indole seriesAntiviral Research, 2013
- Some pathways to overcoming drug resistance of influenza a virus to adamantane derivativesPharmaceutical Chemistry Journal, 2012
- Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidolAntiviral Research, 2009
- Arbidol: A Broad-Spectrum Antiviral Compound that Blocks Viral FusionCurrent Medicinal Chemistry, 2008
- Structural basis for the function and inhibition of an influenza virus proton channelNature, 2008
- Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concernThe Lancet, 2005
- The conformation of the pore region of the M2 proton channel depends on lipid bilayer environmentProtein Science, 2005